<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:department>Pharmacy</gtr:department><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E89C3602-0FB4-4044-A918-58966B8A10B2"><gtr:id>E89C3602-0FB4-4044-A918-58966B8A10B2</gtr:id><gtr:name>University of Reading</gtr:name><gtr:address><gtr:line1>Whiteknights House</gtr:line1><gtr:line2>PO Box 217</gtr:line2><gtr:line4>Reading</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>RG6 6AH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/106C9420-652F-4004-BCBC-21B9D3819E83"><gtr:id>106C9420-652F-4004-BCBC-21B9D3819E83</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>Alfryn</gtr:otherNames><gtr:surname>Lewis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL010933%2F1"><gtr:id>AFF1A5A1-087D-4C16-9CD7-D8B3045B87D1</gtr:id><gtr:title>Dissecting the role of LRRK2 in the regulation of autophagy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L010933/1</gtr:grantReference><gtr:abstractText>Parkinson's disease is an incurable brain disease that afflicts over 125,000 people in the UK, a number that will increase as the population ages. It is caused by cells dying in the part of the brain that helps control movement. At the moment we do not have a treatment that can be used to slow down or treat the cause of the disease, and so an important aim of scientific research into Parkinson's is to develop new drugs. Over the past decade we have learned a lot about the processes in the brain that lead to cells dying in Parkinson's disease by looking at rare cases where the disease is inherited in families. By identifying mutations in the genes that cause Parkinson's in these families we can study the changes in the brain that can lead to disease. This proposal looks at one of these genes, called LRRK2 (pronounced lurk2). Mutations in LRRK2 are the most common genetic cause of Parkinson's, responsible for about 6000 cases in the UK. We now know that subtle changes in LRRK2 (not as potent as mutations) can increase the risk of developing the more common, sporadic type of Parkinson's. This makes LRRK2 a very interesting gene as a potential new drug target. What makes it even more attractive as a drug target is that it has two pockets, called enzyme domains, which can be occupied by small chemical compounds (drugs) to change how it functions. This project focuses on one aspect of what LRRK2 does - looking at how it might be involved in a process called autophagy (pronounced ort-oh-fay-gee). Autophagy is one of the ways in which cells in the body get rid of waste, and we already know that when there are problems with autophagy rubbish builds up and can cause cells to die - a process that is very important in brain diseases like Parkinson's and Alzheimer's. Work from my laboratory shows that when you use a drug to turn LRRK2 &amp;quot;off&amp;quot;, binding to one of those enzyme pockets, autophagy is switched on in human cells that we can grow in a dish. What we are looking at with this project is exactly how this happens, and what other genes are involved in the process. We are also going to look at what mutations in LRRK2 do to change autophagy. We think that mutations might slow down autophagy, which could lead to rubbish building up in the brain over the years and eventually causing enough brain cells to die to make the person with the mutation develop Parkinson's. Finding out what LRRK2 does, and how these mutations change its behavior, is going to be very important for the drug companies who are trying to develop new compounds to treat Parkinson's. It will give them ways in which to measure how active LRRK2 is in cells, which in turn can be used to judge how successful a new drug is at changing that activity, and might uncover new ways to target LRRK2 in the brain. All of this will be critical for developing new drugs for Parkinson's - something that is of huge importance to all of those people who already have the disease and those who will develop it in the future.</gtr:abstractText><gtr:technicalSummary>Mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). Recent genome wide association studies have identified variation at the LRRK2 locus as a significant risk factor for idiopathic PD, linking the Mendelian and sporadic forms of Parkinson's. In combination with the presence in the LRRK2 open reading frame of two enzymatic active sites (a kinase and a GTPase), these facts make LRRK2 one of the most attractive drug targets for PD. This proposal investigates the role of LRRK2 in the regulation of autophagy. Data from my group and from other laboratories around the world have revealed that altering LRRK2 function, either by inhibition, knockout, knockdown or mutation, impacts on autophagy although the precise mechanism remains obscure. We have preliminary data that localizes LRRK2 downstream of mTORC1 in the regulation of autophagy, as chemical inhibition of LRRK2 kinase activity results in an induction of autophagy in the absence of any impact of translational targets of mTORC1 (S6 and 4E-BP1). In this new investigator research grant, I will use a combination of cellular and chemical approaches to manipulate LRRK2 in order to establish the exact point at which LRRK2 intersects with the induction of autophagy, specifically examining the phosphorylation of ULK1 and ATG13 as potential effectors for LRRK2s inhibitory impact on autophagy. In parallel to this, I will examine the impact of mutations in LRRK2 upon the regulation of autophagy at the endogenous level using fibroblasts isolated from individuals harbouring mutations in LRRK2 and age/sex matched controls. Preliminary data suggests that mutations result in a decreased ability to enter autophagy upon starvation, and so in this proposal I will carry out a detailed examination of autophagic flux, along with an examination of the impact of LRRK2 mutations on key regulators of the induction of autophagy using in vitro and cellular models.</gtr:technicalSummary><gtr:potentialImpactText>The data generated by this proposal will have implications for a wide range of beneficiaries beyond an immediate academic audience. LRRK2 is a priority drug target for Parkinson's disease (PD), and understanding the normal function of LRRK2 will have major implications for drug discovery programs directed at this gene. A number of multinational pharmaceutical companies (including GSK, Pfizer, Genentech and Eli Lilly) have programs to develop compounds that modify the activity of LRRK2, with the bulk of this effort directed towards the development of kinase activity inhibitors. By the end of this project, we will have a clear idea of how inhibiting LRRK2's kinase activity alters autophagy, data that will be of great importance to the pharmaceutical sector in their efforts to target this gene. According to a recent estimate, PD costs between &amp;pound;449 million and &amp;pound;3.3 billion to the UK economy (Findley LJ, Parkinsonism and Related Disorders 13: S8-S12, 2007), and it is clear that a therapy for this disorder would be of great economic significance within the UK and around the globe. In more human terms, a disease modifying therapy for PD will have a huge impact on the 125,000 people in the UK who have PD and the tens of thousands who will go on to develop the disorder in the coming decade, including a large number with mutations in LRRK2. 

Beyond PD, the LRRK2 locus has also been implicated in Inflammatory Bowel disease, cancer and leprosy. Although our understanding of the links between LRRK2 and these disorders is not as advanced as for PD, a clearer understanding of LRRK2's biology and role in autophagy has potential impacts in terms of drug development efforts in each of these three disease areas. Given the efforts being directed towards developing drugs to target LRRK2, repurposing of these compounds for testing in other disorders would be a natural follow up to studies in PD - and the data generated by this proposal will have implications for our understanding of h LRRK2 may be linked to these disorders, aiding this process. There are an estimated 120,000 people in the UK living with Ulcerative Colitis, with a further 60,000 living with Crohn's disease (the two most common forms of inflammatory bowel disease, estimates from Crohn's and Colitis UK). Although not life threatening, these disorders are extremely debilitating and there is an active ongoing research effort to develop new treatments - into which this research can feed.

LRRK2 has been linked to oncogenesis by a number of studies, although the exact nature of these links is unclear. Developing novel drugs to target cancer is, however, a key medical goal and the information generated by this proposal will be of relevance to understanding LRRK2's role in cancer by illuminating its basic biological function, data which in the longer term will impact on the efforts to develop drugs to target cancer in the future.

Leprosy is a chronic bacterial infection of the peripheral nerves and mucosa, and if untreated can be severely disabling. It is extremely rare in the UK, but is still an ongoing health problem in South Asia, Africa and South America with a worldwide incidence of over 200,000 (data from WHO). Thankfully multidrug therapy for leprosy is very effective, but given the ongoing issues with multidrug resistance in Tuberculosis, caused by a bacterium closely related to the causative agent of leprosy, the development of further candidate drugs for Leprosy should be encouraged, with repurposed LRRK2 drugs falling into this category. 

Finally, autophagy more broadly is an area of increasing interest from a biomedical drug discovery point of view. A greater understanding of the mechanisms governing the initiation of autophagy, an aspect of this process that the data generated by this proposal will be directly relevant to, will have an impact across a wide swathe of drug discovery for the disorders to which autophagy has been linked.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-05-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-05-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>354213</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Sharon Tooze at CRUK</gtr:description><gtr:id>0AE9C942-6437-4CD0-8506-829411A3C1D5</gtr:id><gtr:impact>Several research papers</gtr:impact><gtr:outcomeId>54620eed7c2d13.31327086-1</gtr:outcomeId><gtr:partnerContribution>Dr Tooze has provided us with antibody and cell reagents</gtr:partnerContribution><gtr:piContribution>We have been investigating LRRK2 and autophagy, carrying out cellular assays</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Collaboration with Max Gutierrez at NIMR</gtr:description><gtr:id>A5E9AE3D-2B4F-4438-9623-8583E6E265C7</gtr:id><gtr:impact>Grant from the Michael J. Fox foundation</gtr:impact><gtr:outcomeId>54620f931d9333.53357362-1</gtr:outcomeId><gtr:partnerContribution>Dr Gutierrez has been investigating a role for LRRK2 in mycobacterial infection and propagation</gtr:partnerContribution><gtr:piContribution>Providing research reagents (LRRK2 inhibitors, cells and antibodies) as well as intellectual input</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC Radio 4 Inside Science Parkinson's Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>30C1AA61-C127-4962-BD10-402640C76209</gtr:id><gtr:impact>I was interviewed by the BBC Radio 4 programme &amp;quot;Inside Science&amp;quot;, commenting on a recent publication on Parkinson's disease and gut microbiota</gtr:impact><gtr:outcomeId>58c0243a4c1f58.33200347</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parkinson's UK public lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0E0234CE-3FCD-4029-B4B1-A149AD499392</gtr:id><gtr:impact>The lecture, on the genetics of Parkinson's disease, was followed by a lively question and answer session involving the audience.

I had a number of contacts from patients with additional questions about my research</gtr:impact><gtr:outcomeId>54620d73be2056.67278807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 Inside Science Mouse models interview</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>61DF9E74-CC68-44A0-A8F4-C7B2724345DF</gtr:id><gtr:impact>I was interviewed on the BBC Radio 4 programme &amp;quot;Inside Science&amp;quot; for a segment on the utility and drawbacks of mouse models for neurodegenerative disease</gtr:impact><gtr:outcomeId>58c02499d95268.19153781</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits to Parkinson's UK local branches</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>41B3A8BA-BA63-43F8-A377-7EC32B559FA6</gtr:id><gtr:impact>I have visited groups around the southeast, including Epsom, Ashford and Dartford, over the past three years. Have presented on a number of subjects including my research and how genetics is helping us to understand Parkinson's

specific donations to my research grant</gtr:impact><gtr:outcomeId>UG2WfhEKudn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rewired movement for hope event (bloomsbury)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E81B04C5-F40B-472E-929D-8F9A33477A78</gtr:id><gtr:impact>200 members of the public attended an evening of art and science focused on neuroscience. I gave a short talk on how genetics is informing our understanding of neurodegeneration

Occurred very recently, feedback will be available at a later date.</gtr:impact><gtr:outcomeId>ckRqwL7Hmcn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CD556919-D123-4CCD-B5DC-A65245A883A0</gtr:id><gtr:impact>I have visited a number of schools in and around Reading over the last five years, describing my career path in biomedical research and presenting a snapshot of my research into Parkinson's disease

Difficult to measure without specific metrics. I have had a number of students visiting my lab as a result of talks.</gtr:impact><gtr:outcomeId>SH3621opsak</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>95042</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M017222/1</gtr:fundingRef><gtr:id>55881916-5810-46E3-8644-6D990B142B58</gtr:id><gtr:outcomeId>5698d788c45e17.75233214</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institutes of Health/University of Reading Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>National Institute on Aging</gtr:fundingOrg><gtr:id>69CDA8D1-4963-4EEB-9005-F028319E5F8F</gtr:id><gtr:outcomeId>5698d7d6594d71.76970443</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant Neuroscience and Mental Health board</gtr:description><gtr:end>2021-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N026004/1</gtr:fundingRef><gtr:id>F6062422-2D52-4E22-AE04-FEF886D6E4E5</gtr:id><gtr:outcomeId>583c050c9c3608.69489702</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A145B0D9-41DA-416C-A553-951C24C6C6C3</gtr:id><gtr:title>The LRRK2 signalling system.</gtr:title><gtr:parentPublicationTitle>Cell and tissue research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7cc28640bc4770eb6ba54019d6eb7d5"><gtr:id>e7cc28640bc4770eb6ba54019d6eb7d5</gtr:id><gtr:otherNames>Price A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-766X</gtr:issn><gtr:outcomeId>5a58937f0e46b9.91056708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52873314-C930-41D8-B3AA-E1C28F1E2522</gtr:id><gtr:title>Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson's disease on chromosome 7p15.3.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5e3cac4ddaeb729d77bdb3126ca0b50"><gtr:id>b5e3cac4ddaeb729d77bdb3126ca0b50</gtr:id><gtr:otherNames>Murthy MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>5a34f5eb6e9f78.95023656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>388E306C-20E2-413C-8099-F94CEEA68FAF</gtr:id><gtr:title>Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences.</gtr:title><gtr:parentPublicationTitle>Briefings in bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1467-5463</gtr:issn><gtr:outcomeId>583c04640ddb74.50901907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E9F0266-FB89-4041-A7B7-EBD94BD64DE6</gtr:id><gtr:title>Genetic, structural, and molecular insights into the function of ras of complex proteins domains.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/865abf3616d9e50b08ef99c603e1db55"><gtr:id>865abf3616d9e50b08ef99c603e1db55</gtr:id><gtr:otherNames>Civiero L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>pm_540e199e19989537b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0A48D85-3B95-4C84-B1C5-19966204D7BE</gtr:id><gtr:title>PAK6 Phosphorylates 14-3-3? to Regulate Steady State Phosphorylation of LRRK2.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/865abf3616d9e50b08ef99c603e1db55"><gtr:id>865abf3616d9e50b08ef99c603e1db55</gtr:id><gtr:otherNames>Civiero L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5a58937ebd7a49.60197119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE5A2064-A875-4A92-960B-7442F731FBD9</gtr:id><gtr:title>GTP binding controls complex formation by the human ROCO protein MASL1.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93fc073fbe54ba9ea4dd041091d5dffa"><gtr:id>93fc073fbe54ba9ea4dd041091d5dffa</gtr:id><gtr:otherNames>Dihanich S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>pm_15751_21_24286120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6084B6-5AD9-47C2-B8BD-9EE877BE23D4</gtr:id><gtr:title>Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation.</gtr:title><gtr:parentPublicationTitle>Molecular neurodegeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cf5553107e55c233b68c1efaf1db243"><gtr:id>8cf5553107e55c233b68c1efaf1db243</gtr:id><gtr:otherNames>Kiely AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-1326</gtr:issn><gtr:outcomeId>55fb5689560608.89521718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B9F7F04-3706-4160-A8CA-15EB314BD6F2</gtr:id><gtr:title>Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/865abf3616d9e50b08ef99c603e1db55"><gtr:id>865abf3616d9e50b08ef99c603e1db55</gtr:id><gtr:otherNames>Civiero L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>55fb568912b867.49090029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D24ABB2D-1CA2-4044-B334-66E19DF9C102</gtr:id><gtr:title>Rare variants in LRRK1 and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c29f4932a9c0faa81ab4ed1cecedefd0"><gtr:id>c29f4932a9c0faa81ab4ed1cecedefd0</gtr:id><gtr:otherNames>Schulte EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>pm_15751_21_24241507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36466879-E5BD-490C-94BF-631626E92329</gtr:id><gtr:title>Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b4dc64d68a5e9ae3c76aac3d96735f"><gtr:id>55b4dc64d68a5e9ae3c76aac3d96735f</gtr:id><gtr:otherNames>Bandopadhyay R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>585d5447017c25.30390485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42F6EEE3-4E16-4E0B-96ED-48664BFA7A04</gtr:id><gtr:title>Genetic and phenotypic characterization of complex hereditary spastic paraplegia.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/697536feebefd233256c0907479ff552"><gtr:id>697536feebefd233256c0907479ff552</gtr:id><gtr:otherNames>Kara E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>585d7294c10dc9.53193506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC4EA040-BF22-40C4-97D9-F5BAD3198E59</gtr:id><gtr:title>Cellular processes associated with LRRK2 function and dysfunction.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1daa9c552889120e7495abd55bdca24d"><gtr:id>1daa9c552889120e7495abd55bdca24d</gtr:id><gtr:otherNames>Wallings R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5538db4b793189.72641914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FC205DE-DB62-4D5F-812F-F5DBB2129775</gtr:id><gtr:title>Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6f56a59bf0c127ea59004421ab9871"><gtr:id>0b6f56a59bf0c127ea59004421ab9871</gtr:id><gtr:otherNames>Lubbe SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>580e2a341f2505.66412749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21D4B09E-A495-4162-BB04-E20BAA7352E4</gtr:id><gtr:title>Parkinson's disease: From human genetics to clinical trials.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b737ee2349761ab1fb1ecedc727a8cf"><gtr:id>3b737ee2349761ab1fb1ecedc727a8cf</gtr:id><gtr:otherNames>van der Brug MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>55fb56898aa010.71405481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13997ECB-4F45-42B3-B6CE-9623123BA336</gtr:id><gtr:title>Computational analysis of the LRRK2 interactome.</gtr:title><gtr:parentPublicationTitle>PeerJ</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5537c0702032b9.60437552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF7F21E-E92A-4270-B147-DF84EA72B391</gtr:id><gtr:title>mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>580e2a33ed61b9.66834137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5814C213-CC97-4A07-B00E-C8BD247B909F</gtr:id><gtr:title>Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeab5dcf8187a67e2a1d2237a3100588"><gtr:id>aeab5dcf8187a67e2a1d2237a3100588</gtr:id><gtr:otherNames>Tsika E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544138af8420d0.95015348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75290D32-EC29-4A3A-BA07-A131A41015FB</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>56cc06067c6c00.95560908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9914B005-2B00-45F8-962D-B6422C1DA43A</gtr:id><gtr:title>Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bc79c6d1bd646b80a6e83cb1ed16ead"><gtr:id>8bc79c6d1bd646b80a6e83cb1ed16ead</gtr:id><gtr:otherNames>Mamais A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>544138af4e9b99.98571505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F50BEEC-BCE2-4994-90BD-BD6CDB712D79</gtr:id><gtr:title>Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfd9da3a1a116b93eccfc7b5c2c94d54"><gtr:id>dfd9da3a1a116b93eccfc7b5c2c94d54</gtr:id><gtr:otherNames>Cogo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>5a2fd3404e9834.97971287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE1FF7FC-84BF-4CDC-9673-6015B1AA6684</gtr:id><gtr:title>The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>58b84de96910e8.58174306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C388F4F-3A07-41AE-8C6E-94A91BCEC6AE</gtr:id><gtr:title>Weighted Protein Interaction Network Analysis of Frontotemporal Dementia.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9daf1044ffaa78c220fa83b15b9c753"><gtr:id>b9daf1044ffaa78c220fa83b15b9c753</gtr:id><gtr:otherNames>Ferrari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>5874aae3269780.13417714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9483C4E8-59AE-4688-B3F3-7EEE8F4C9DA8</gtr:id><gtr:title>Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba827a97c3d3145072b7a8beef79432d"><gtr:id>ba827a97c3d3145072b7a8beef79432d</gtr:id><gtr:otherNames>Noyce AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a35e55d955b99.42003431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D106726-4324-48F0-A3CA-B6C2BC8A95EC</gtr:id><gtr:title>Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7fe1dd55034bc0ac4a8b7df96fbd147"><gtr:id>b7fe1dd55034bc0ac4a8b7df96fbd147</gtr:id><gtr:otherNames>Tomkins JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>5aa439f1ea5584.27056276</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L010933/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>